Estrogen Receptor (ER) Signalling Pathway in Cancers
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (29 February 2020) | Viewed by 43411
Special Issue Editor
Interests: ovarian cancer; cell signaling; experimental therapeutics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear colleagues,
The importance of estrogen receptor signalling is well recognised in estrogen-dependent cancers, most notably in breast cancer. The two major estrogen receptor subtypes (ERα and ERβ) regulate different functions and actions. While the genomic role of these receptors has long been recognised to mediate transcription through DNA binding, there has also been increasing recognition of the nongenomic role of the cell membrane receptor GPER1 (GPR30). Cell signalling pathways that cross-talk with estrogen signalling are important in influencing the dominance of this pathway within cancer cells and will influence estrogen (and anti-estrogen) sensitivity. Further understanding of these interacting pathways is required to bypass resistance and to help develop therapeutic strategies for hormone-resistant cancers.
This Special Issue welcomes original articles and reviews related to estrogen receptor signalling and also pathways that interact and cross-talk with estrogen signaling, giving rise to hormone resistance in cancer.
Dr. Simon Langdon
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- estrogen receptor
- cell signaling
- human cancers
- pathway cross-talk
- anti-estrogen
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.